Browse MAT1A

Summary
SymbolMAT1A
Namemethionine adenosyltransferase I, alpha
Aliases MATA1; SAMS1; S-adenosylmethionine synthetase; MAT 1; MAT-I/III; S-adenosylmethionine synthetase isoform typ ......
Chromosomal Location10q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location -
Domain PF02773 S-adenosylmethionine synthetase
PF02772 S-adenosylmethionine synthetase
PF00438 S-adenosylmethionine synthetase
Function

Catalyzes the formation of S-adenosylmethionine from methionine and ATP. The reaction comprises two steps that are both catalyzed by the same enzyme: formation of S-adenosylmethionine (AdoMet) and triphosphate, and subsequent hydrolysis of the triphosphate.

> Gene Ontology
 
Biological Process GO:0000096 sulfur amino acid metabolic process
GO:0001887 selenium compound metabolic process
GO:0006520 cellular amino acid metabolic process
GO:0006555 methionine metabolic process
GO:0006556 S-adenosylmethionine biosynthetic process
GO:0006730 one-carbon metabolic process
GO:0006732 coenzyme metabolic process
GO:0006790 sulfur compound metabolic process
GO:0009063 cellular amino acid catabolic process
GO:0009066 aspartate family amino acid metabolic process
GO:0009068 aspartate family amino acid catabolic process
GO:0009087 methionine catabolic process
GO:0009108 coenzyme biosynthetic process
GO:0016054 organic acid catabolic process
GO:0032259 methylation
GO:0044272 sulfur compound biosynthetic process
GO:0044282 small molecule catabolic process
GO:0046395 carboxylic acid catabolic process
GO:0046500 S-adenosylmethionine metabolic process
GO:0051186 cofactor metabolic process
GO:0051188 cofactor biosynthetic process
GO:0051259 protein oligomerization
GO:0051260 protein homooligomerization
GO:0051262 protein tetramerization
GO:0051289 protein homotetramerization
GO:1901565 organonitrogen compound catabolic process
GO:1901605 alpha-amino acid metabolic process
GO:1901606 alpha-amino acid catabolic process
Molecular Function GO:0004478 methionine adenosyltransferase activity
GO:0016765 transferase activity, transferring alkyl or aryl (other than methyl) groups
GO:0098601 selenomethionine adenosyltransferase activity
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG hsa00270 Cysteine and methionine metabolism
hsa01100 Metabolic pathways
hsa01230 Biosynthesis of amino acids
Reactome R-HSA-211859: Biological oxidations
R-HSA-1430728: Metabolism
R-HSA-71291: Metabolism of amino acids and derivatives
R-HSA-2408508: Metabolism of ingested SeMet, Sec, MeSec into H2Se
R-HSA-156581: Methylation
R-HSA-156580: Phase II conjugation
R-HSA-2408522: Selenoamino acid metabolism
R-HSA-1614635: Sulfur amino acid metabolism
Summary
SymbolMAT1A
Namemethionine adenosyltransferase I, alpha
Aliases MATA1; SAMS1; S-adenosylmethionine synthetase; MAT 1; MAT-I/III; S-adenosylmethionine synthetase isoform typ ......
Chromosomal Location10q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between MAT1A and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolMAT1A
Namemethionine adenosyltransferase I, alpha
Aliases MATA1; SAMS1; S-adenosylmethionine synthetase; MAT 1; MAT-I/III; S-adenosylmethionine synthetase isoform typ ......
Chromosomal Location10q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of MAT1A in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolMAT1A
Namemethionine adenosyltransferase I, alpha
Aliases MATA1; SAMS1; S-adenosylmethionine synthetase; MAT 1; MAT-I/III; S-adenosylmethionine synthetase isoform typ ......
Chromosomal Location10q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of MAT1A in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.9560.228
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.1730.903
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)871.5420.158
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-1.5910.0169
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-2.3460.023
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.6490.595
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.0480.962
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15111.3230.377
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-1.3740.388
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.2660.876
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.1190.957
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.1790.605
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of MAT1A in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277301.4-1.41
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275901.7-1.71
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21179.55.93.61
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)8612.5012.51
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.79.1-1.41
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 382703.7-3.70.415
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 221307.7-7.70.371
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolMAT1A
Namemethionine adenosyltransferase I, alpha
Aliases MATA1; SAMS1; S-adenosylmethionine synthetase; MAT 1; MAT-I/III; S-adenosylmethionine synthetase isoform typ ......
Chromosomal Location10q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of MAT1A. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolMAT1A
Namemethionine adenosyltransferase I, alpha
Aliases MATA1; SAMS1; S-adenosylmethionine synthetase; MAT 1; MAT-I/III; S-adenosylmethionine synthetase isoform typ ......
Chromosomal Location10q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of MAT1A. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by MAT1A.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolMAT1A
Namemethionine adenosyltransferase I, alpha
Aliases MATA1; SAMS1; S-adenosylmethionine synthetase; MAT 1; MAT-I/III; S-adenosylmethionine synthetase isoform typ ......
Chromosomal Location10q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of MAT1A. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolMAT1A
Namemethionine adenosyltransferase I, alpha
Aliases MATA1; SAMS1; S-adenosylmethionine synthetase; MAT 1; MAT-I/III; S-adenosylmethionine synthetase isoform typ ......
Chromosomal Location10q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of MAT1A expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolMAT1A
Namemethionine adenosyltransferase I, alpha
Aliases MATA1; SAMS1; S-adenosylmethionine synthetase; MAT 1; MAT-I/III; S-adenosylmethionine synthetase isoform typ ......
Chromosomal Location10q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between MAT1A and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolMAT1A
Namemethionine adenosyltransferase I, alpha
Aliases MATA1; SAMS1; S-adenosylmethionine synthetase; MAT 1; MAT-I/III; S-adenosylmethionine synthetase isoform typ ......
Chromosomal Location10q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting MAT1A collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting MAT1A.
ID Name Drug Type Targets #Targets
DB00118AdemetionineSmall MoleculeAMD1, AS3MT, CBS, CMTR1, COMT, GNMT, MAT1A, MAT2A8
DB031913-Oxiran-2ylalanineSmall MoleculeMAT1A1
DB03611L-2-amino-4-methoxy-cis-but-3-enoic acidSmall MoleculeMAT1A1